124 related articles for article (PubMed ID: 31618089)
1. Ibrutinib-Associated Reversible Cardiomyopathy.
Liang SH; Chiu CF; Bai LY
J Oncol Pract; 2019 Dec; 15(12):671-673. PubMed ID: 31618089
[No Abstract] [Full Text] [Related]
2. Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
Furtado M; Wang ML; Munneke B; McGreivy J; Beaupre DM; Rule S
Br J Haematol; 2015 Jul; 170(1):131-4. PubMed ID: 25559624
[No Abstract] [Full Text] [Related]
3. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
[No Abstract] [Full Text] [Related]
4. The Muddied Waters of Ibrutinib Therapy.
Schamroth Pravda M; Schamroth Pravda N; Lishner M
Acta Haematol; 2019; 141(4):209-213. PubMed ID: 30943468
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
Tucker DL; Naylor G; Kruger A; Hamilton MS; Follows G; Rule SA
Br J Haematol; 2017 Jul; 178(2):327-329. PubMed ID: 27197509
[No Abstract] [Full Text] [Related]
6. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.
Tobinai K; Uchida T; Fukuhara N; Nishikawa T
Int J Hematol; 2019 Mar; 109(3):366-368. PubMed ID: 30623356
[No Abstract] [Full Text] [Related]
7. Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
Ruella M; Soubeyran P
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):432-436. PubMed ID: 27913512
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
Vitagliano O; Trastulli F; Cacace F; Leone S; Memoli M; Scalia G; Notarangelo M; Mainolfi CG; De Renzo A; Pane F
Leuk Lymphoma; 2018 Jul; 59(7):1734-1737. PubMed ID: 29019439
[No Abstract] [Full Text] [Related]
9. Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
Jiang H; Lwin T; Zhao X; Ren Y; Li G; Moscinski L; Shah B; Tao J
Br J Haematol; 2019 Jan; 184(2):298-302. PubMed ID: 29383700
[No Abstract] [Full Text] [Related]
10. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib-associated Serositis in Mantle Cell Lymphoma.
Styskel BA; Lopez-Mattei J; Jimenez CA; Stewart J; Hagemeister FB; Faiz SA
Am J Respir Crit Care Med; 2019 Jun; 199(12):e43-e44. PubMed ID: 30802411
[No Abstract] [Full Text] [Related]
12. Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
Diamantopoulos PT; Psichogiou M; Pantazatou A; Zervakis K; Rougala N; Giannakopoulou N; Daikos G; Viniou NA
Ann Hematol; 2017 Jun; 96(6):1049-1050. PubMed ID: 28247056
[No Abstract] [Full Text] [Related]
13. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
[TBL] [Abstract][Full Text] [Related]
16. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
Srour SA; Lee HJ; Nomie K; Ye H; Chen W; Oriabure O; Romaguera J; Wang ML
Br J Haematol; 2018 May; 181(4):561-564. PubMed ID: 28369820
[No Abstract] [Full Text] [Related]
17. Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Kaur V; Swami A
J Oncol Pharm Pract; 2017 Apr; 23(3):235-239. PubMed ID: 26970573
[TBL] [Abstract][Full Text] [Related]
18. B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.
Zhang L; Nomie K; Zhang H; Bell T; Pham L; Kadri S; Segal J; Li S; Zhou S; Santos D; Richard S; Sharma S; Chen W; Oriabure O; Liu Y; Huang S; Guo H; Chen Z; Tao W; Li C; Wang J; Fang B; Wang J; Li L; Badillo M; Ahmed M; Thirumurthi S; Huang SY; Shao Y; Lam L; Yi Q; Wang YL; Wang M
Clin Cancer Res; 2017 Aug; 23(15):4212-4223. PubMed ID: 28348046
[No Abstract] [Full Text] [Related]
19. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
Wang ML; Lee H; Chuang H; Wagner-Bartak N; Hagemeister F; Westin J; Fayad L; Samaniego F; Turturro F; Oki Y; Chen W; Badillo M; Nomie K; DeLa Rosa M; Zhao D; Lam L; Addison A; Zhang H; Young KH; Li S; Santos D; Medeiros LJ; Champlin R; Romaguera J; Zhang L
Lancet Oncol; 2016 Jan; 17(1):48-56. PubMed ID: 26640039
[TBL] [Abstract][Full Text] [Related]
20. Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.
Varughese T; Taur Y; Cohen N; Palomba ML; Seo SK; Hohl TM; Redelman-Sidi G
Clin Infect Dis; 2018 Aug; 67(5):687-692. PubMed ID: 29509845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
